Stifel Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9
Stifel analyst Bradley Canino maintains $Zentalis Pharmaceuticals(ZNTL.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 45.3%
Stifel Nicolaus Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Morgan Stanley Downgrades Zentalis Pharmaceuticals(ZNTL.US) to Hold Rating, Cuts Target Price to $8
Morgan Stanley analyst Michael Ulz downgrades $Zentalis Pharmaceuticals(ZNTL.US)$ to a hold rating, and adjusts the target price from $38 to $8.According to TipRanks data, the analyst has a success
Maintaining Hold on Zentalis Pharmaceuticals Amidst Positive Regulatory Developments and Upcoming Clinical Milestones
TD Cowen Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating
TD Cowen analyst Tyler Van Buren maintains $Zentalis Pharmaceuticals(ZNTL.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.7% and a total average return of 2.1%
Top Midday Gainers